Taiho Oncology Presents Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compounds at the 109th Annual Meeting of the American Association for Cancer Research

 (PRNewsfoto/Taiho Oncology, Inc.)PRINCETON, N.J., April 13, 2018 /PRNewswire/ — Taiho Oncology, Inc. today announced clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) for the treatment of patients with advanced gastrointestinal tumors, and two investigational compounds, TAS-120 and TAS-114, both currently…

Share this post